Cargando...
Systemic treatments for hepatocellular carcinoma: challenges and future perspectives
Sorafenib has been the only approved systemic treatment of hepatocellular carcinoma (HCC) for almost a decade. Recently, two new drugs showed positive results in two Phase III studies. The RESORCE trial identified regorafenib as a valid second-line treatment for patients progressing to sorafenib, th...
Gardado en:
| Publicado en: | Hepat Oncol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Future Medicine Ltd
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6168042/ https://ncbi.nlm.nih.gov/pubmed/30302192 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep-2017-0020 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|